Jump to content
RemedySpot.com

Two new studies point to risks for people taking the diabetes drug Avandia (3 articles)

Rate this topic


Recommended Posts

Guest guest
Posted

Two new studies point to risks for people taking the diabetes drug Avandia

By Rob Stein

Washington Post Staff Writer

Tuesday, June 29, 2010

Two teams of researchers have produced powerful new evidence that the

diabetes drug Avandia increases the risk of heart problems and strokes,

renewing questions about the safety of the medication.

One analysis, involving more than 35,500 people, found that Avandia

significantly raises the chances of a heart attack. The second, a

federal analysis of more than 227,500 Medicare patients -- the largest

such study to date -- found that the drug boosts the risk for strokes,

heart failure and death.

The new research, released Monday, should prompt the Food and Drug

Administration to remove the drug from the market, according to the

researchers who led the analyses and several drug-safety advocates.

" There's no reason to keep this drug on the market, " said E.

Nissen, a Cleveland Clinic cardiologist who conducted one of the

analyses and has long criticized the drug. " This is a harmful drug. "

In a statement, GlaxoKline, which makes Avandia, stood by the

medication, saying many other, more reliable studies have found no

evidence the drug is unsafe. The studies that found no risk were better

designed and therefore more reliable, the company says.

" Taken together, these trials show that Avandia does not increase the

overall risk of heart attack, stroke or death, " the company said in a

statement.

A Senate investigation released earlier this year concluded that

GlaxoKline knew about the possible risks of Avandia for years but

failed to sufficiently warn the FDA and consumers.

The new data will be considered next month at special joint meeting of

two FDA advisory panels to reevaluate Avandia's status, an agency

official said.

" These are very important papers and will contribute to our evaluation

of the safety of this medication, " said M. Sharfstein, the

agency's principal deputy commissioner.

Avandia had once been one of the world's most popular drugs, with sales

exceeding $3 billion annually. The drug was approved in 1999. It treats

Type 2 diabetes, the most common form of the disease, by sensitizing the

body to insulin, controlling blood sugar levels. It was considered

widely effective. But a series of studies have raised questions about

whether it raises the risk for cardiovascular problems, a leading cause

of death among diabetics. That prompted the FDA to issue a warning about

the drug's safety, causing sales to plummet, but the agency decided in

2007 against removing it from the market.

Coming on the heels of safety concerns about the blockbuster painkiller

Vioxx and other prescription medications, as well as a series of

high-profile food safety cases, questions about Avandia have fueled

criticism that the FDA is lax in regulating the food and drug industries.

ad_icon

" I'm hoping with a new administration and new leadership they will act

differently, " Nissen said. " This is a defining moment for the new

administration. "

But J. Graham of the FDA's Center for Drug Evaluation and Research

said he doubted the agency would pull the drug. A longtime critic of

Avandia and the FDA's drug safety record, he conducted the second new

analysis.

" FDA, unfortunately, has not changed, " Graham said. " It has not improved

its approach to drug safety. It does not value drug safety. "

Sharfstein, however, defended the FDA, saying the agency wanted to

examine the latest data before making a decision. " FDA is committed to

making decisions about Avandia based on all the best available science, "

he said.

In one of the new analyses, Nissen and a colleague pooled data from 56

studies involving 35,531 people, including 19,509 who took Avandia. In a

paper released online by the Archives of Internal Medicine, the

researchers concluded that the drug increased the risk for heart attacks

from 28 percent to 39 percent. The pair calculated that the drug would

cause one heart attack among every 37 to 52 people who used it for five

years.

In the second analysis, Graham and his colleagues analyzed Medicare

records for 227,571 people who took either Avandia or another diabetes

drug called Actos from 2006 to 2009.

They found that those who took Avandia were 27 percent more likely to

have a stroke, 25 percent more likely to develop heart failure and 14

percent more likely to die during the study period than were those who

took Actos. Based on the findings, released online by the Journal of the

American Medical Association, the researchers estimated that there would

be one heart attack, death, stroke or heart failure in every 60 people

who took the drug for one year.

http://www.washingtonpost.com/wp-dyn/content/article/2010/06/28/AR2010062802089.\

html?wpisrc=nl_cuzhead

==========================================================

Public release date: 28-Jun-2010

Contact: Kolonick

kolonib@...

JAMA and Archives Journals

New meta-analysis demonstrates heart risks associated with rosiglitazone

Eleven years after the introduction of the diabetes drug rosiglitazone,

data from available clinical trials demonstrate an increased risk for

heart attack associated with its use and suggest an unfavorable

benefit-to-risk ratio, according to a report posted online today that

will appear in the July 26 print issue of Archives of Internal Medicine,

one of the JAMA/Archives journals. The study was published online in

advance of an upcoming Food and Drug Administration meeting that will

review the safety of rosiglitazone.

Rosiglitazone was approved in 1999 to treat hyperglycemia (high blood

glucose levels) among patients with type 2 diabetes, according to

background information in the article. Concerns about the cardiovascular

safety of rosiglitazone first arose in 2007, when a meta-analysis

demonstrated a significantly increased risk for myocardial infarction

(heart attack) and a borderline significant increase for cardiovascular

death. The debate over the medication's safety has continued during the

past three years, and the U.S. Senate Committee on Finance recently

released a report providing additional details about internal analyses

conducted by the U.S. Food and Drug Administration and by

GlaxoKline (GSK), the drug's manufacturer.

No large, definitive cardiovascular outcomes trials have been conducted

with rosiglitazone. However, as a consequence of a 2004 court settlement

in New York, GSK was required to post clinical trial results on a public

web site. E. Nissen, M.D., and Kathy Wolski, M.P.H., of The

Cleveland Clinic Foundation, searched this GSK data and MEDLINE through

February 2010 and identified 56 trials involving 35,531 patients, 19,509

of whom received rosiglitazone and 16,022 who received control medications.

In the combined studies, rosiglitazone therapy was associated with a

significantly increased risk of myocardial infarction by an estimated 28

percent to 39 percent, although the risk of cardiovascular death was not

increased. " An alternative analysis that included trials with no

cardiovascular events found a similar hazard, " the authors write.

" Subgroups classified by study duration and comparator drug also showed

elevated odds ratio estimates. "

" These findings are consistent with prior meta-analyses conducted by

GSK, the FDA and most independent investigators demonstrating an

increased risk of myocardial infarction in patients treated with

rosiglitazone, " they continue. " The FDA has announced that it will

conduct an advisory committee meeting in July 2010 to consider whether

to remove rosiglitazone from the market. "

The mechanisms by which rosiglitazone may cause cardiovascular harm are

not clear, the authors note, but could involve increases in low-density

lipoprotein (LDL, or " bad " cholesterol) levels or genetic effects

associated with the production of an enzyme linked to plaque rupture.

" The public health implications of these results are considerable. There

are more than 23 million persons with diabetes in the United States

alone and nearly 300 million worldwide. Cardiovascular disease is the

leading cause of death in patients with type 2 diabetes, representing

approximately 68 percent of all causes of mortality, " the authors

conclude. " Although hyperglycemia has been associated with an increased

risk of microvascular adverse events, there are now 12 classes of drugs

that are approved to lower blood glucose levels, including insulin.

Because no unique benefits of rosiglitazone use have been identified,

administration of this agent solely to lower blood glucose levels is

difficult to justify. "

###

(Arch Intern Med. 2010;170[12]:(doi:10.1001/archinternmed.2010.207).

Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: Dr. Nissen has received research support from

AstraZeneca, Atherogenics, Eli Lilly, Novartis, Pfizer, Resverlogix,

Takeda, Daiichi-Sankyo and Sanofi-Aventis through The Cleveland Clinic

Center for Clinical Research in within the last five years. He has

consulted for a number of pharmaceutical companies without financial

compensation. All honoraria, consulting fees or any other payments from

any for-profit entity are paid directly to charity, so he receives

neither income nor tax deduction. Please see the article for additional

information, including other authors, author contributions and

affiliations, financial disclosures, funding and support, etc.

For more information, contact JAMA/Archives Media Relations at

312/464-JAMA (5262) or e-mail mediarelations@....

http://www.eurekalert.org/pub_releases/2010-06/jaaj-nmd062410.php

==============================================

Public release date: 28-Jun-2010

Contact: J. Graham, M.D., M.P.H.

david.graham1@...

JAMA and Archives Journals

Type 2 diabetes medication rosiglitazone associated with increased

cardiovascular risks and death

A new study published online today by JAMA shows that among patients age

65 years and older, rosiglitazone (a medication for treating Type 2

diabetes) is associated with an increased risk of stroke, heart failure,

and all-cause mortality (death) when compared with pioglitazone (another

medication for diabetes). The study was published online today in

advance of an upcoming Food and Drug Administration meeting that will

review the safety of rosiglitazone. The paper will appear in the July 28

print issue of JAMA.

" Rosiglitazone and pioglitazone are the only thiazolidinediones (a class

of drugs for treating diabetes) currently marketed in the United

States, " the authors provide as background information. " Studies have

suggested that the use of rosiglitazone may be associated with an

increased risk of serious cardiovascular events compared with other

treatments for type 2 diabetes. "

J. Graham, M.D., M.P.H., from the Center for Drug Evaluation and

Research, U.S. Food and Drug Administration, Silver Springs, MD and

colleagues, evaluated data from 227,571 Medicare beneficiaries (average

age, 74.4 years) who started treatment with rosiglitazone or

pioglitazone through a Medicare Part D prescription drug plan from July

2006 through June 2009. The patients were followed for up to three years

after the initiation of the medications.

" During follow-up, there were 1,746 acute myocardial infarctions [heart

attacks] (21.7 percent fatal), 1,052 strokes (7.3 percent fatal), 3,307

hospitalizations for heart failure (2.6 percent fatal), and 2,562 deaths

for all causes among cohort members, " the authors report. Analysis

showed no differences in the risk for heart attack between rosiglitazone

and pioglitazone, but " …our study found that rosiglitazone was

associated with a 1.25-fold increase in risk of heart failure compared

with pioglitazone, " and " …these data suggest that rosiglitazone was

associated with a 1.27-fold increased risk of stroke and a 1.14-fold

increased risk of death compared with pioglitazone, " according to the

authors.

In conclusion, the authors write: " …in a population of more than 227,000

patients 65 years or older who initiated treatment with a

thiazolidinedione, we found that, compared with pioglitazone,

rosiglitazone was associated with an increased risk of stroke, heart

failure, and death and the composite of AMI (heart attack), stroke,

heart failure or death. " (JAMA.doi:10.1001/jama.2010.920. Available to

the media pre-embargo at www.jamamedia.org.)

Editor's Note: This study was funded by the Office of the Assistant

Secretary for Planning and Evaluation (ASPE), the Centers for Medicare &

Medicaid Services (CMS), and the U.S. Food and Drug Administration

(FDA). Please see the article for additional information, including

other authors, author contributions and affiliations, financial

disclosures, funding and support, etc.

Editorial: Rosiglitazone and the Case for Safety Over Certainty

In an accompanying editorial, Juurlink, M.D., Ph.D., of the

Sunnybrook Research Institute; the Departments of Medicine, Pediatrics

and Health Policy, Management, and Evaluation at the University of

Toronto; and the Institute for Clinical Evaluative Sciences, Toronto,

highlights the importance of the findings of the report by Graham and

colleagues in terms of understanding the risks of rosiglitazone.

Dr. Juurlink writes, " The epilogue of the rosiglitazone story has yet to

be written, but a few observations can now be made with confidence.

First, there is no direct evidence that rosiglitazone prevents vascular

events in patients with diabetes. Second, converging lines of evidence

suggest that rosiglitazone is less safe than pioglitazone, whereas no

data suggest that the converse might be true. Third, because the

evidence to date is not conclusive, differing views have emerged on how

to proceed in the face of uncertainty. … Whether rosiglitazone and

pioglitazone really do have different cardiovascular safety profiles is

an intriguing question but one with a misplaced focus. Accumulating

concerns about rosiglitazone make it difficult to advance a cogent

argument why, exactly, a patient might want to receive the drug or why a

physician would choose to prescribe it when there is an available and

quite possibly safer alternative. " (JAMA.doi:10.1001/jama.2010.954.

Available to the media pre-embargo at www.jamamedia.org)

Editor's Note: Please see the article for additional information author

affiliations, financial disclosures, funding and support, etc.

###

For more information, contact JAMA/Archives Media Relations at

312/464-JAMA (5262) or e-mail mediarelations@.... To

contact editorial author Juurlink, M.D., Ph.D., call Deborah

Creatura at or e-mail: deborah.creatura@....

http://www.eurekalert.org/pub_releases/2010-06/jaaj-t2d062410.php

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...